In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Type

Type

Guidance programme

Showing 1 to 2 of 2

TitleTypeExpected publication date
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]Technology appraisal guidance
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All